VEGFA and neoplasm: VEGF is certainly one of the most important molecules involved in tumor angiogenesis and it became the first target for the anti-angiogenic drug development [95]: to date, bevacizumab, ramucirumab, and aflibercept, which are respectively a humanized antibody against VEGF-A, a humanized antibody against VEGFR2 and a decoy receptor binding VEGF-A, are approved for use in mCRC patients.